This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m 2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3–4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.
CITATION STYLE
Kaspers, G. J. L., Niewerth, D., Wilhelm, B. A. J., Scholte-van Houtem, P., Lopez-Yurda, M., Berkhof, J., … Zwaan, C. M. (2018). An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 181(4), 523–527. https://doi.org/10.1111/bjh.15233
Mendeley helps you to discover research relevant for your work.